

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Understanding Low Vaccine Uptake in African, Caribbean, and Black Populations Relative to Public Health in High-Income Countries: A Scoping Review Protocol

Dr. Josephine Etowa (JE)¹

Sheryl Beauchamp (SB)²

Victoria Cole (VC)³

Affiliations

- ¹School of Nursing, Faculty of Health Sciences, University of Ottawa.
josephine.etowa@uottawa.ca.
- ²School of Nursing, Faculty of Health Sciences, University of Ottawa.
SBeau144@uottawa.ca.
- ³Research Librarian, University of Ottawa.
vcole@uottawa.ca

29

Abstract

30 **Background:** Vaccination has significantly contributed to reducing once common and even
31 deadly infectious diseases, yet vaccine hesitancy threatens the emergence of vaccine-preventable
32 diseases. The COVID-19 pandemic has caused the need for the largest mass vaccination
33 campaign ever undertaken to date; however, African, Caribbean, and Black (ACB) populations
34 have shown both a disproportionately high degree of negative impacts from the pandemic and
35 the lowest willingness to become vaccinated. Low vaccination rates in this vulnerable population
36 are a pinnacle concern in public health, as low vaccination rates in ACB communities may both
37 be the result of health inequities, as well as further exacerbate them.

38 **Purpose:** To explore low vaccine uptake in African, Caribbean, and Black (ACB) populations
39 relative to public health in high-income countries. **Objectives:** 1) To identify concepts and
40 boundaries of existing evidence sources on low vaccine uptake in ACB populations; 2) To map
41 out the evidence on the concepts and boundaries and to identify gaps in the research; and 3) To
42 determine existing interventions to improve low vaccine uptake in the study population.

43 **Methodology:** This scoping review follows the Joanna Briggs Institute (JBI) framework for
44 scoping reviews, supplemented by the Preferred Reporting Items for Systematic Reviews
45 extension (PRISMA-ScR). Any deviations from the JBI recommendations are stated. **Theoretical**
46 **underpinnings** of the intersectionality approach will be used to help interpret the complexities of
47 health inequities in the ACB population, including those related to the social determinants of
48 health (SDOH). **Search strategies** were developed by an information specialist (VC) and peer-
49 reviewed using the PRESS guideline. The search was conducted in: MEDLINE(R) ALL
50 (OvidSP), Embase (OvidSP), CINAHL (EBSCOHost), APA PsycInfo (OvidSP), Cochrane
51 Central Register of Controlled Trials (OvidSP), Cochrane Database of Systematic Reviews

52 (OvidSP), Allied & Complimentary Medicine Database (Ovid SP), and Web of Science.
53 **Eligibility criteria** are based on the Population, Concept, Context (PCC) framework. The
54 inclusion criteria for this study included evidence -sources with a primary focus on African,
55 Caribbean, and Black populations, and other related terms; high-income countries as defined by
56 the World Bank where ACB populations are considered a minority; all service providers; English
57 and French languages; all types of evidence sources; related to low vaccine uptake and
58 alternative terms; all vaccines; and publications from 2020- current (July 19th, 2022). **The**
59 **screening, selection, and extraction** of the evidence sources were completed by the AVA
60 research team. **Analysis** was done through the process of Thematic Mapping, and **summarization**
61 **and presentation** of the findings were done through a narrative description organized using the
62 socioeconomic model (SEM) as a framework.

63

64 **Ethics and dissemination:** This study used published evidence sources with no human or
65 animal participants; thus, ethical approval and consent to participate are not applicable.

66 **Dissemination:** This will occur through peer-reviewed open-access journals and conferences
67 that target stakeholders in public health, vaccination campaigns and overcoming inequities in
68 healthcare.

69

70

71

72

73

74

75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97

Introduction

African, Caribbean, and Black (ACB) populations are not only vulnerable due to health inequities, as evidenced by higher rates of SARS- CoV-2 infections, hospitalizations, and associated mortalities, but are also the least willing to receive the vaccine.[1–3] The COVID-19 pandemic has been one of the greatest public health threats of modern times, bringing societal, community, and individual challenges to the forefront; these impacts have been intensified in racialized communities, as pre-existing inequities and vulnerabilities are exacerbated.[4,5] These inequities are strongly influenced by socioeconomic factors, referred to as the social determinants of health (SDOH); for example, death rates in ACB populations were higher in areas with a greater incidence of adverse SDOH.[5,6] Although race-based data collection remains inconsistent in Canada, the cities of Ottawa and Toronto reported 1.5-5 times the increase in COVID-19 infection rates among racialized communities; these findings are consistent with other high-income countries, including the United States (US) and the United Kingdom (UK).[5,7,8] These highlighted COVID-19 racial inequities regarding disease and vaccinations in ACB populations, are not new; public health disparities also occurred during the 2009 H1N1 pandemic, and high rates of vaccination mistrust have been reported for the Human Papillomavirus (HPV) vaccine, H1N1 vaccine, and influenza vaccine.[4,9–12]

The World Health Organization (WHO)[13] defines vaccine hesitancy as the refusal or reluctance to become vaccinated despite available vaccines; the reasons identified include complacency, inconvenience, and lack of confidence. It can result in delayed vaccination or uncertainty in the vaccine even after its administration, which can threaten vaccination programs

98 by leading to decreased coverage and increased risk of vaccine-preventable disease
99 outbreaks.[14,15] Currently, vaccine hesitancy regarding the COVID-19 vaccination threatens
100 the success of the largest mass vaccination campaign ever undertaken to date, both within
101 Canada and globally.[16] However, the importance of addressing vaccine hesitancy reaches
102 beyond its implications for COVID-19, including both current and potential future outbreaks; the
103 coronavirus alone has accounted for three pandemics within the last 20 years, including COVID-
104 19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome
105 (MERS).[17]
106
107 Vaccine uptake has been declining over the past several decades; global coverage dropped from
108 86% in 2019 to 83% in 2020, with the highest rate of children under one, 23 million, not
109 receiving basic vaccines since 2009, and completely unvaccinated children increasing by 3.4
110 million.[18,19] In 2019, the World Health Organization (WHO) listed both vaccine hesitancy
111 and weak primary healthcare as two of the top ten threats to global health; both threaten the
112 success of vaccination campaigns.[13,20]
113
114 In Canada and globally, vaccines significantly prevent and control infectious diseases and are
115 thus a cornerstone of public health.[21] Historically, vaccines have reduced disease-specific
116 mortality rates, including smallpox, rabies, polio, the plague, typhoid and many more, and have
117 significantly decreased infant mortality rates globally[18]; over 3 million child deaths are
118 estimated to be prevented each year globally, through vaccinations.[22] Despite vaccinations
119 being considered to be one of the public health's greatest success stories, vaccine hesitancy is
120 influenced by the confidence in the competencies of health professionals and health

121 services.[23,24] Vigilance is required to maintain and increase vaccine uptake, especially in
122 vulnerable populations, as people’s behaviors and willingness to follow recommended measures
123 are the most powerful tools against viral spread.[25,26]

124
125 Public health interventions must go beyond the COVID-19 vaccine and seek to understand the
126 historical basis for vaccine hesitancy, while adapting to the current dynamics and preparing for
127 future outbreaks. If public health fails to implement appropriate interventions, health inequities
128 threaten to become even more vast, as those who are socioeconomically disadvantaged often
129 have health conditions that are exacerbated by inadequate healthcare.[10,27,28] Further research
130 is needed to determine why ACB populations have the lowest level of vaccine acceptance in
131 Canada than other high-income countries.[3,29]. These disparities need to be promptly
132 addressed; however, a greater understanding about the implications of challenges faced by
133 vulnerable populations on vaccine uptake and public health is required.[10,28]

134
135 Prior to embarking on creating service provider (i.e., healthcare providers, policymakers, and
136 community organization providers) interventions applicable to vaccine hesitancy in vulnerable
137 ACB populations, associated concepts and their boundaries must be clarified. Due to the
138 explorative nature and broad overview desired, a scoping review (ScR) approach has been
139 chosen. There has been a steady increase in the use of ScRs, as they are valuable for health
140 researchers to establish the breadth of data available.[30,31] Due to this ScR not undergoing
141 assessment of bias, including critically appraising the evidence sources, the implication for
142 service providers would be better served through a systematic review however, if the evidence
143 sources reveal any potential implication to service provider practice, service provider knowledge

144 and research, these will be stated.[32,33] The essential characteristics of this ScR will include
145 pre-planning through the creation of a protocol, transparency of the processes involved, and
146 clarity of concepts.[31]

147
148 A preliminary search in JBI Evidence Synthesis, Cochrane Database of Systematic Reviews,
149 Cumulative Index to Nursing and Allied Health Literature (CINAHL) and PubMed, for existing
150 scoping reviews, systematic reviews and protocols was performed on January 31st, 2022, relating
151 to the determinants of vaccine hesitancy and ACB populations. This search was done using
152 Several terms (refer to S1 File), and the keywords such as “vaccine hesitancy” and “Black”
153 yielded the most relevant results, namely, the following four reviews: One rapid systematic
154 review related to COVID-19 vaccine hesitancy and minority ethnic groups in the UK[34]; one
155 scoping review related to COVID-19 vaccine hesitancy globally[35]; and two systematic
156 reviews, one related to vaccine hesitancy in the US[36] and the second related to vaccine
157 acceptance in different populations in the US.³⁸ In addition, on June 22nd, 2022, VC searched the
158 Open Science Framework (OFS) site and found the ScR protocol on racial and ethnic minorities
159 and Indigenous population groups living in high-income countries.[38] To avoid duplication of
160 findings, this ScR included all vaccines, ACB populations specifically, all high-income countries
161 where the ACB population is considered a minority population, and evidence sources from 2020-
162 2022.

163
164 To develop a clear study structure, and to help guide the selection of evidence sources that align
165 with the research question, the Joanna Briggs Institute (JBI) recommended PCC (population,
166 concepts, context) framework was used; PCC was also used to compose the title as per the JBI

167 framework.[32] The research question is: What are the determinants and interventions of low
168 vaccine uptake in African, Caribbean, and Black (ACB) populations relative to healthcare in
169 high-income countries? Whereby the population (P) is ACB populations and service providers,
170 the concept (C) is low vaccine uptake, and the context (C) is healthcare in high income.

171
172 The aim of this ScR is to explore low vaccine uptake in ACB populations relative to public
173 health in high-income countries. The objectives are: 1) To identify concepts and boundaries of
174 existing evidence sources on low vaccine uptake in ACB populations; 2) To map the evidence on
175 the concepts and boundaries and to identify gaps in the research; and 3) To determine existing
176 interventions to improve low vaccine uptake in the study population. These objectives were
177 achieved through systematically reviewing the breadth and types of source evidence available.
178 This scoping review is part of a larger study examining vaccine uptake in the ACB community
179 which has been funded by the Public Health Agency of Canada. Funding number: # 2122-HQ-
180 000318. The study received full ethical approval from the University of Ottawa Research Ethics
181 Board (REB). University of Ottawa ethics approval certificate number: H-12-21-7558.

182

183 **Methodology**

184

185 The Joanna Briggs Institute (JBI) scoping review (ScR) methodological framework by Peters et
186 al.[32] will help provide organization to this ScR, which aims to outline different types of
187 evidence on the determinants of vaccine hesitancy in ACB populations, and the gaps for future
188 research. The nine steps of the framework are; 1) defining and aligning the objectives and
189 research question; 2) developing and aligning the inclusion criteria with the objectives and

190 question; 3) describing the planned approach to evidence searching, selection, data extraction
191 and evidence presentation; 4) searching the evidence; 5) selecting the evidence; 6) extracting the
192 evidence; 7) analyzing the evidence; 8) presenting the evidence; and 9) summarizing the
193 evidence in relation to the purpose of the review, making conclusions, and noting any
194 implications of the findings.[32]

195

196 *Developing and Aligning the Inclusion Criteria with the Objectives and Questions*

197

198 The inclusion criteria are: evidence-sources with a primary focus on African, Caribbean, and
199 Black (ACB) populations and related terms; high-income countries as defined by the World
200 Bank[39] where ACB populations are considered a minority; all service providers; English and
201 French languages; all types of evidence sources; related to low vaccine uptake and alternative
202 terms; all vaccines; and publications from 2020-current (July 19th, 2022).

203

204 The exclusion criteria are: Evidence sources prior to 2020, racialized and minority populations
205 that are not ACB, and any evidence source that does not meet the inclusion criteria.

206

207 **Eligibility Criteria with Explanation in PCC Framework.**

208

209 The population (P) includes any person, community, or population that is identified as African,
210 Caribbean, and Black (ACB) or related terms. This population has been chosen because of their
211 high levels of vulnerability and high propensity for vaccine hesitancy. The evidence source must
212 describe the population in a high-income country. This is to aid in exploring the roles of race and

213 ethnicity on the health of ACB populations in Canada, which has often been extrapolated from
214 US and UK-derived statistics; two countries that systematically collect race-based health data.
215 The case of collecting race-based data in Canada can be challenging.[8,40,41] Other racialized
216 populations within high-income countries will be excluded, as they have their own distinct
217 identities and face unique inequities; therefore, a separate ScR, to which they are the primary
218 focus, may be more appropriate.[8]

219
220 The concept (C) of determinants of vaccine hesitancy encompasses reasons for unwillingness to
221 be vaccinated and other similarly meaning sentiments. Due to the increasing trend of vaccine
222 hesitancy, measures should be taken to identify and understand underlying factors and to inform
223 the creation of effective and targeted solutions.[18,19,42] In this ScR, attempts will be made to
224 explore all relevant concepts and their boundaries, with the only exclusion pertaining to the dates
225 of publication. Publication dates will be restricted to December 2020 to current, to provide
226 contemporary evidence sources that are also inclusive to the public availability of the COVID-19
227 vaccine.[3,18,19,43]

228
229 The context (C) of public health has no exclusion criteria; both vulnerable populations and
230 vaccinations are a primary concern of public health.

231
232 Despite the ambiguity of some terms used within the research question, these are consistent with
233 Arkey and O'Malley,[44] which recommends maintaining a wide approach to generate a breadth
234 of literature; more parameters could be added once a general scope and volume of evidence
235 sources is obtained.

236

237 ***Planned Approach to Evidence Searching, Selection, and Data Extraction***

238

239 The intention of this section is to provide a transparent and auditable search strategy and to
240 provide structure to the proposed ScR.[32] The search strategy can be found in S1 File.

241

242 **Planned Approach to Evidence Searching.**

243

244 A comprehensive search strategy will be developed to identify relevant evidence sources based
245 on the research questions and PCC framework. To increase the breadth of the ScR, source
246 evidence will be open to all types, including primary studies, secondary studies, grey literature,
247 poster presentations, abstracts, reports, and so on. Only French and English evidence sources will
248 be used due to feasibility reasons, as these are the primary languages of the researchers, and
249 translation is not available. In addition, only evidence sources with a primary focus on African,
250 Caribbean, and/or Black populations will be included so that issues specific to this target
251 population are addressed. Furthermore, the time frame will be restricted to 2020-current (July
252 19th, 2022) to provide contemporary findings, given the dynamic nature of vaccine uptake,
253 particularly during the COVID-19 pandemic. All evidence sources from the searches will be
254 recorded in the Preferred Reporting Items for Systematic Reviews (PRISMA) flowchart adapted
255 from Page et al.[45]

256

257 The search strategy will follow the three-step process recommended by JBI[32]; step 1 will
258 involve an initial search to identify a list of terms; step 2 will be the implementation of the search
259 strategy based on the identified terms, and step 3 will involve a hand search of the
260 references from selected evidence sources, direct contacting of authors were performed due to
261 time limitations.

262

263 ***Step 1: Initial Search to Identify the List of Relevant Terms.***

264

265 To help capture the breadth of low vaccine uptake in ACB populations relative to public health
266 in high-income countries, a piloting of keywords and Medical Subject Headings (MeSH) terms
267 were conducted by research team members SB and JE with information specialist VC June 2022.
268 Initial searches were used to inform the iterative process of the ScR, by potentially refining and
269 allowing for new sources and keywords to be added.[32]

270 Search strategies will be developed by an information specialist (VC) and peer-reviewed using
271 the PRESS guideline.[46] The search will be conducted in: MEDLINE(R) ALL (OvidSP),
272 Embase (OvidSP), CINAHL (EBSCOHost), APA PsycInfo (OvidSP), Cochrane Central Register
273 of Controlled Trials (OvidSP), Cochrane Database of Systematic Reviews (OvidSP), Allied &
274 Complimentary Medicine Database (Ovid SP), and Web of Science. Each database will be
275 searched from its inception until July 19, 2022, for the concept of “Vaccine uptake” and
276 “African, Black and Caribbean” populations using a combination of subject headings and
277 keywords.

278 ***Step 2: Implementation of Search Strategy Based on Identified Terms.***

279 Drafting the search strategy will be informed by two Cochrane reviews [47,48] and a protocol in
280 the Open Science Framework [38] for the concept of vaccine uptake. The concept of African,
281 Caribbean and Blacks will be informed by consulting Hope et al.'s [49] systematic review. No
282 search filters or language limits will be used, and publication restrictions will be applied to the
283 search.

284
285 ***Step 3: Hand Searches and Reference List.***

286 Research team members (MA, PB, GO, KS, RS, ECO, ID, SJ, HO, and SB). will manually
287 search the retrieved publications' reference lists to find all relevant studies that they would
288 consider. All references that satisfy the eligibility requirements will be checked against our initial
289 list of articles for duplication, and any that are found to be duplicates will be deleted. Additional
290 hand searches will not be done due to time constraints. All other sources of evidence will be
291 listed in the PRISMA flowchart.

292
293 **The Planned Approach to Selection**

294 All evidence sources from the database searches will be uploaded into the software program
295 Covidence, which will remove duplicate articles. They will then be screened by their title and
296 abstract based on the aforementioned eligibility criteria by two members of the research team
297 (MA, PB, GO, RS, ECO, ID, SJ, SB) being resolved by a third team member. During this
298 process, any additional duplicate articles found will be removed. Articles will be selected based
299 on the title, and abstract screening, followed by the full text by two research team members (MA,
300 PB, GO, KS, RS, ECO, ID, SJ, SB), and a third member will resolve any conflicts. The number

301 of excluded articles will be recorded in the PRISMA flowchart with the rationale for their
302 exclusion.

303

304 **The Planned Approach to Data Extraction**

305 A critical appraisal of the selected evidence sources will not be performed; it is not typically
306 performed in an ScR.[32] This helps maintain a breadth of evidence from various sources;
307 including, primary studies, secondary studies, grey literature, websites, blogs, reports etc.
308 However, risk for bias is created by not critically appraising the evidence sources, and thus
309 findings will not be synthesized.[32] However, in order to create a descriptive narrative of the
310 evidence sources, an extraction table will be created to provide an analytical framework.[44]

311

312 To calibrate the table, reviewers will independently extract three evidence sources, which will
313 subsequently be compared and, any discrepancies between the reviewers will be discussed until
314 at least a 75% agreement is achieved. At this point, any remaining issues will be recorded, and
315 the full extraction of all sources of evidence will occur.[32] Creating the table is an iterative
316 process, and modifications may be made as through the same process as more evidence
317 emerges.[50] Refer to S2 File for a template of the extraction table; any further changes made
318 will be documented and a rationale will be provided. The template for this table contains general
319 information and information that can help inform the research questions and objectives; namely,
320 first author, date, country of origin, population, vaccination type, study design, sample size,
321 findings, and conclusion. Given that several different types of evidence sources are anticipated, it
322 is not expected that all categories in the general extraction table will be completed for each
323 evidence source; not applicable (N/A) will be written, where appropriate. However, the extracted

324 data from each evidence source will align with the research question and objectives based on
325 reviewing its entire text. Microsoft Word will be used during the extraction process to record and
326 organize the data. The extracted information will be used to inform the collation and
327 summarization of the findings from the evidence sources.


328

329 ***Planned Approach to Collation and Summarization and Presentation of Evidence***

330 Thematic mapping (TM) [51] will be used to collate and summarize the extracted data, as it is
331 ideal for accommodating the multiple types of evidence sources in this study. This method also
332 allows for the production of themes while maintaining the breadth of information within each
333 theme through the creation of subthemes (descriptive and analytical themes), which is consistent
334 with Arkey and O'Malley,[44] which has stated that a ScR seeks to explore the breadth of
335 existing evidence sources and not to qualify the evidence or provide generalizable robust
336 findings and Peters et al.[32] which has stated that results should be descriptively mapped rather
337 than synthesized. The critical appraisal step in TM will not be performed, as it is unnecessary for
338 a ScR.

339

340 Thematic Mapping is a three-phase process:



341
342
343
344
345
346
347
348
349
350
351
352
353
354

Figure 1 Thematic mapping. This diagram from Etowa et al.[51] illustrates the steps in thematic mapping. These steps will be followed in our study with the exception of the qualitative appraisal which is not required in a scoping review.[32]

The aim of Phase 1 will be to create initial codes and descriptive themes which are informed by the theoretical underpinnings used in this study; namely, intersectionality, the social determinants of health (SDOH), and the socio-economic model (SEM) as they relate to low vaccine uptake in African, Caribbean, and Black (ACB) populations relative to public health in high-income countries. In this phase, the articles will be divided by article types. To ensure methodological rigor two reviewers will independently code the extracted data from each article; namely, MA and SB will extract the qualitative articles, GO and SB will extract the quantitative

355 articles, KS and SB will extract the commentaries, and RS and SB will extract the mixed
356 methods articles, any conflicts will be resolved by a third researcher JB. Consistent with
357 Objective 1 of this study, which is to identify concepts and boundaries of existing evidence
358 sources on low vaccine uptake in ACB populations, the generated codes from each type of article
359 will be used to create descriptive themes which will then further define the context and
360 boundaries of concepts within each group. The descriptive themes will be based on grouping the
361 codes by similarities and differences until a consensus was reached.

362
363 Within Phase 2, analytical themes will be created to gain further insight into the characteristics of
364 the descriptive themes that reflected the content within each article grouping (qualitative,
365 quantitative, mixed method and commentaries) separately. The descriptive themes from each
366 article will be grouped based on similarities and differences into analytical themes through
367 induction and interpretation that is consistent with the PCC research question and the theoretical
368 underpinnings as in Phase 1. The iterative process of creating the final analytical themes will
369 conclude when a consensus was reached between the research team members.

370
371 Within Phase 2, main themes will be created to give a broad overview of findings based on the
372 similarities and differences across all groups (article types). These main themes will be used to
373 map the evidence on the concepts and boundaries, identify gaps in the research (Objective 2),
374 and determine existing interventions to improve low vaccine uptake in the study population
375 (Objective 3).

376
377 A descriptive narrative summary will be used to describe these findings because an ScR's
378 analysis is descriptive by nature.[32]

379

380 **Ethics Approval and Consent to Participate**

381 This study will use published evidence sources with no human or animal participants; thus
382 ethical approval and consent to participate will not be applicable.

383

384

385

Discussion

386

387 In order to limit bias, this ScR procedure will predefine the search question, objectives,
388 methodology, eligibility criteria, search methods, data extraction techniques, summary, and the
389 presentation of anticipated findings.[32] This ScR will provide a broad perspective from a
390 variety of evidence sources, with a focus on understanding the circumstances and limitations of
391 ACB communities' low vaccination rates. Moreover, it will aid in determining the range of
392 available evidence sources available and identify research gaps. This ScR will gain insight into
393 different vulnerable populations by pinpointing the factors that result in low vaccine uptake in
394 ACB populations and will offer insight into the policies, practices, and research that can be used
395 to meet the needs of ACB and other vulnerable populations.

396

397

398

Strengths and Limitations

399 The anticipated broad selection and types of evidence sources will include grey literature, to
400 maximize the breadth of findings thus, strengthening this scoping review. However, the dynamic
401 nature of vaccination hesitancy, which will necessitate surveillance and acquiring new
402 information to remain current, limits this study. Another restriction that could result in the loss of
403 necessary data is the language limitation to English and French. Another drawback is that the

404 evidence sources might not be critically appraised, which might impact the study's validity,
405 ability to be validated, and ability to synthesize and analyze the extracted findings.

406 Despite the limitations, this scoping review will help to identify, define, and highlight inequities
407 that may impact health behaviors associated with low vaccine uptake, because it strives to
408 increase the understanding of factors that determine low vaccine uptake in ACB populations. It is
409 anticipated that this ScR will improve service provider knowledge in this respect and will
410 contribute to the creation of adequate interventions.

411 ***Dissemination***

412 ***Dissemination***
413
414 The results from this scoping review will be disseminated through peer-reviewed open-access
415 journals and conferences targeting public health stakeholders, vaccination campaigns and
416 overcoming inequities in healthcare.

417

418 **Supporting Information**

419 S1 File

420 The Medline database search strategy:

421 Ovid MEDLINE(R) ALL <1946 to July 18, 2022>

422
423 1 vaccination refusal/ or vaccination hesitancy/ 1303
424 2 exp Vaccines/ 263498
425 3 immunization/ or immunization programs/ 64648
426 4 vaccination/ or mass vaccination/ or vaccination coverage/ 102268
427 5 or/2-4 330753
428 6 attitude to health/ or health knowledge, attitudes, practice/ or "treatment adherence and
429 compliance"/ or "patient acceptance of health care"/ or patient compliance/ or medication
430 adherence/ or treatment refusal/ 329383
431 7 5 and 6 10621
432 8 ((vaccin* or immunis* or immuniz* or innocul*) adj2 (attitude* or perspective* or
433 perception* or belief* or concern* or view or views or accept* or uptake or adhere* or

434 nonadhere* or comply or noncompl* or complian* or conform* or challeng* or barrier* or
 435 facilitat* or enabl* or opportunit* or concern* or hesita* or refus* or reject* or abstain* or
 436 declin* or resist* or object* or deny* or denier* or denial* or decision* or nonattend* or non-
 437 attend* or reluctan* or delay* or behavior* or behaviour* or confidence or willingness or
 438 coverage or trust or distrust or mistrust or skeptic or intention*).tw,kf. 37602
 439 9 1 or 7 or 8 42405
 440 10 exp "Ethnic and Racial Minorities"/ or racial groups/ or minority groups/ or
 441 ethnicity/ 100515
 442 11 blacks/ or african americans/ 95100
 443 12 (african* or arfro* or caribbean* or black*).tw,kf. 345606
 444 13 10 or 11 or 12 445515
 445 14 9 and 13 2222

446 S2 File

	Article	Country	Population	Vaccine	Design	Sample Size	Findings	Conclusion
1								
2								
2								

447
 448
 449

450
 451 **Acknowledgements**

452
 453 We thank Nigèle Langlois, MLIS (Research Librarian, University of Ottawa Library) for peer
 454 review of the MEDLINE search strategy.

455

456

References

- 457 1. The Canadian COVID-19 Genomics Network (CanCOGeN). Understanding the impact of
458 COVID-19 on Black Canadians. In: GenomeCanada [Internet]. 26 Feb 2021 [cited 10 Jan
459 2023]. Available: [https://genomecanada.ca/understanding-impact-covid-19-black-](https://genomecanada.ca/understanding-impact-covid-19-black-canadians/)
460 [canadians/](https://genomecanada.ca/understanding-impact-covid-19-black-canadians/)
- 461 2. Eissa A, Lofters A, Akor N, Prescod C, Nnorom O. Increasing SARS-CoV-2 vaccination
462 rates among Black people in Canada. *CMAJ*. 2021;193: E1220–E1221.
463 doi:10.1503/cmaj.210949
- 464 3. Statistics Canada. COVID-19 vaccine willingness among Canadian population groups. 26
465 Mar 2021 [cited 10 Jan 2023]. Available: [https://www150.statcan.gc.ca/n1/pub/45-28-](https://www150.statcan.gc.ca/n1/pub/45-28-0001/2021001/article/00011-eng.htm)
466 [0001/2021001/article/00011-eng.htm](https://www150.statcan.gc.ca/n1/pub/45-28-0001/2021001/article/00011-eng.htm)
- 467 4. Kricorian K, Turner K. COVID-19 Vaccine Acceptance and Beliefs among Black and
468 Hispanic Americans. *PLOS ONE*. 2021;16: e0256122. doi:10.1371/journal.pone.0256122
- 469 5. Public Health Agency of Canada. CPHO Sunday Edition: The Impact of COVID-19 on
470 Racialized Communities. 21 Feb 2021 [cited 10 Jan 2023]. Available:
471 [https://www.canada.ca/en/public-health/news/2021/02/cpho-sunday-edition-the-impact-of-](https://www.canada.ca/en/public-health/news/2021/02/cpho-sunday-edition-the-impact-of-covid-19-on-racialized-communities.html)
472 [covid-19-on-racialized-communities.html](https://www.canada.ca/en/public-health/news/2021/02/cpho-sunday-edition-the-impact-of-covid-19-on-racialized-communities.html)
- 473 6. Dalsania AK, Fastiggi MJ, Kahlam A, Shah R, Patel K, Shiao S, et al. The Relationship
474 Between Social Determinants of Health and Racial Disparities in COVID-19 Mortality. *J*
475 *Racial and Ethnic Health Disparities*. 2022;9: 288–295. doi:10.1007/s40615-020-00952-y
- 476 7. Dryden O, Nnorom O. Time to dismantle systemic anti-Black racism in medicine in
477 Canada. *CMAJ*. 2021;193: E55–E57. doi:10.1503/cmaj.201579
- 478 8. Thompson E, Edjoc R, Atchessi N, Striha M, Gabrani-Juma I, Dawson T. COVID-19: A
479 case for the collection of race data in Canada and abroad. *CCDR*. 2021;47: 300–304.
480 doi:10.14745/ccdr.v47i78a02
- 481 9. Shafiq M, Elharake JA, Malik AA, McFadden SM, Aguolu OG, Omer SB. COVID-19
482 Sources of Information, Knowledge, and Preventive Behaviors Among the US Adult
483 Population. *Journal of Public Health Management and Practice*. 2021;27: 278.
484 doi:10.1097/PHH.0000000000001348
- 485 10. Acharya A, Lam K, Danielli S, Ashrafian H, Darzi A. COVID-19 vaccinations among
486 Black Asian and Minority Ethnic (BAME) groups: Learning the lessons from influenza.
487 *International Journal of Clinical Practice*. 2021;75: e14641. doi:10.1111/ijcp.14641
- 488 11. Olanipekun T, Effoe VS, Olanipekun O, Igbinomwanhia E, Kola-Kehinde O, Fotzeu C, et
489 al. Factors influencing the uptake of influenza vaccination in African American patients
490 with heart failure: Findings from a large urban public hospital. *Heart & Lung*. 2020;49:
491 233–237. doi:10.1016/j.hrtlng.2019.12.003

- 492 12. Marsh HA, Malik F, Shapiro E, Omer SB, Frew PM. Message Framing Strategies to
493 Increase Influenza Immunization Uptake Among Pregnant African American Women.
494 *Matern Child Health J.* 2014;18: 1639–1647. doi:10.1007/s10995-013-1404-9
- 495 13. World Health Organization (WHO). Ten threats to global health in 2019. [cited 10 Jan
496 2023]. Available: [https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-](https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019)
497 2019
- 498 14. Strategic Advisory Group of Experts (SAGE). Report of the Sage Working Group on
499 Vaccine Hesitancy. In: *The Compass for SBC* [Internet]. 2014 [cited 12 Jan 2023].
500 Available: [https://thecompassforsbc.org/sbcc-tools/report-sage-working-group-vaccine-](https://thecompassforsbc.org/sbcc-tools/report-sage-working-group-vaccine-hesitancy)
501 hesitancy
- 502 15. Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger JA. Vaccine hesitancy. *Human*
503 *Vaccines & Immunotherapeutics.* 2013;9: 1763–1773. doi:10.4161/hv.24657
- 504 16. Koons C. When Nurses Refuse to Get Vaccinated. *Bloomberg.com.* 28 Aug 2021.
505 Available: [https://www.bloomberg.com/news/newsletters/2021-08-28/when-nurses-refuse-](https://www.bloomberg.com/news/newsletters/2021-08-28/when-nurses-refuse-to-get-vaccinated)
506 to-get-vaccinated. Accessed 10 Jan 2023.
- 507 17. Bhagavathula AS, Aldhaleei WA, Rahmani J, Mahabadi MA, Bandari DK. Knowledge and
508 Perceptions of COVID-19 Among Health Care Workers: Cross-Sectional Study. *JMIR*
509 *Public Health Surveill.* 2020;6: e19160. doi:10.2196/19160
- 510 18. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. *Eur J Epidemiol.*
511 2020;35: 325–330. doi:10.1007/s10654-020-00634-3
- 512 19. World Health Organization (WHO). Immunization coverage. 2021a [cited 10 Jan 2023].
513 Available: <https://www.who.int/news-room/fact-sheets/detail/immunization-coverage>
- 514 20. Mayo Clinic. Herd immunity and COVID-19: What you need to know. In: *Mayo Clinic*
515 [Internet]. 2021 [cited 10 Jan 2023]. Available: [https://www.mayoclinic.org/diseases-](https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/herd-immunity-and-coronavirus/art-20486808)
516 conditions/coronavirus/in-depth/herd-immunity-and-coronavirus/art-20486808
- 517 21. Government of Canada (GC). Canadian Immunization Guide: Introduction. 2020 [cited 10
518 Jan 2023]. Available: [https://www.canada.ca/en/public-health/services/canadian-](https://www.canada.ca/en/public-health/services/canadian-immunization-guide/introduction.html)
519 immunization-guide/introduction.html
- 520 22. Oku A, Oyo-Ita A, Glenton C, Fretheim A, Ames H, Muloliwa A, et al. Communication
521 strategies to promote the uptake of childhood vaccination in Nigeria: a systematic map.
522 *Global Health Action.* 2016;9: 30337. doi:10.3402/gha.v9.30337
- 523 23. Center for Disease Control and Prevention (CDC). Overview, History, and How It Works |
524 CDC. 9 Sep 2020 [cited 10 Jan 2023]. Available:
525 <https://www.cdc.gov/vaccinesafety/ensuringsafety/history/index.html>

- 526 24. Nguyen TC, Gathecha E, Kauffman R, Wright S, Harris CM. Healthcare distrust among
527 hospitalised black patients during the COVID-19 pandemic. *Postgraduate Medical Journal*.
528 2022;98: 539–543. doi:10.1136/postgradmedj-2021-140824
- 529 25. Shen SC, Dubey V. Addressing vaccine hesitancy: Clinical guidance for primary care
530 physicians working with parents. *Can Fam Physician*. 2019;65: 175–181.
- 531 26. World Health Organization (WHO). COVID-19 Global Risk Communication and
532 Community Engagement Strategy – interim guidance. 2021b [cited 10 Jan 2023].
533 Available: [https://www.who.int/publications-detail-redirect/covid-19-global-risk-](https://www.who.int/publications-detail-redirect/covid-19-global-risk-communication-and-community-engagement-strategy)
534 [communication-and-community-engagement-strategy](https://www.who.int/publications-detail-redirect/covid-19-global-risk-communication-and-community-engagement-strategy)
- 535 27. Bogart LM, Ojikutu BO, Tyagi K, Klein DJ, Mutchler MG, Dong L, et al. COVID-19
536 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy Among Black
537 Americans Living With HIV. *J Acquir Immune Defic Syndr*. 2021;86: 200–207.
538 doi:10.1097/QAI.0000000000002570
- 539 28. Waisel DB. Vulnerable populations in healthcare. *Current Opinion in Anesthesiology*.
540 2013;26: 186. doi:10.1097/ACO.0b013e32835e8c17
- 541 29. Office for National Statistics. Coronavirus and Vaccine Hesitancy, Great Britain: 31 March
542 to 25 April 2021. 2021 [cited 22 Feb 2023]. Available:
543 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandwell](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandwellbeing/datasets/coronavirusandvaccinehesitancygreatbritain)
544 [being/datasets/coronavirusandvaccinehesitancygreatbritain](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandwellbeing/datasets/coronavirusandvaccinehesitancygreatbritain)
- 545 30. Tricco AC, Lillie E, Zarin W, O’Brien K, Colquhoun H, Kastner M, et al. A scoping review
546 on the conduct and reporting of scoping reviews. *BMC Medical Research Methodology*.
547 2016;16: 15. doi:10.1186/s12874-016-0116-4
- 548 31. Lockwood C, dos Santos KB, Pap R. Practical Guidance for Knowledge Synthesis: Scoping
549 Review Methods. *Asian Nursing Research*. 2019;13: 287–294.
550 doi:10.1016/j.anr.2019.11.002
- 551 32. Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: Scoping
552 reviews - JBI Manual for Evidence Synthesis - JBI Global Wiki. 2020 [cited 10 Jan 2023].
553 Available: <https://synthesismanual.jbi.global>.
- 554 33. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review
555 or scoping review? Guidance for authors when choosing between a systematic or scoping
556 review approach. *BMC Medical Research Methodology*. 2018;18: 143.
557 doi:10.1186/s12874-018-0611-x
- 558 34. Kamal A, Hodson A, Pearce JM. A Rapid Systematic Review of Factors Influencing
559 COVID-19 Vaccination Uptake in Minority Ethnic Groups in the UK. *Vaccines*. 2021;9:
560 1121. doi:10.3390/vaccines9101121

- 561 35. Biswas MR, Alzubaidi MS, Shah U, Abd-Alrazaq AA, Shah Z. A Scoping Review to Find
562 Out Worldwide COVID-19 Vaccine Hesitancy and Its Underlying Determinants. *Vaccines*.
563 2021;9: 1243. doi:10.3390/vaccines9111243
- 564 36. Yasmin F, Najeeb H, Moeed A, Naeem U, Asghar MS, Chughtai NU, et al. COVID-19
565 Vaccine Hesitancy in the United States: A Systematic Review. *Frontiers in Public Health*.
566 2021;9. Available: <https://www.frontiersin.org/articles/10.3389/fpubh.2021.770985>
- 567 37. Salomoni MG, Di Valerio Z, Gabrielli E, Montalti M, Tedesco D, Guaraldi F, et al.
568 Hesitant or Not Hesitant? A Systematic Review on Global COVID-19 Vaccine Acceptance
569 in Different Populations. *Vaccines*. 2021;9: 873. doi:10.3390/vaccines9080873
- 570 38. Thota AB. PROTOCOL: Scoping Review of Interventions to Increase Vaccination Uptake
571 for Racial and Ethnic Minorities and Indigenous Population Groups Living in High-Income
572 Countries. *OSF Preprints*; 2022. doi:10.31219/osf.io/t3y kz
- 573 39. World Bank. High income. 2022 [cited 9 Jun 2022]. Available:
574 <https://data.worldbank.org/country/XD>
- 575 40. Annett C. Inequities in COVID-19 Health Outcomes: The Need for Race- and Ethnicity-
576 Based Data. In: *HillNotes* [Internet]. 8 Dec 2020 [cited 11 Jan 2023]. Available:
577 [https://hillnotes.ca/2020/12/08/inequities-in-covid-19-health-outcomes-the-need-for-race-
578 and-ethnicity-based-data/](https://hillnotes.ca/2020/12/08/inequities-in-covid-19-health-outcomes-the-need-for-race-and-ethnicity-based-data/)
- 579 41. Government of Ontario. Ontario's Regulatory Registry. Government of Ontario, Ministry
580 of Economic Development, Job Creation and Trade; 2021 [cited 11 Jan 2023]. Available:
581 <https://www.ontariocanada.com/registry/view.do?postingId=32967&language=en>
- 582 42. Kumar D, Chandra R, Mathur M, Samdariya S, Kapoor N. Vaccine hesitancy:
583 understanding better to address better. *Israel Journal of Health Policy Research*. 2016;5: 2.
584 doi:10.1186/s13584-016-0062-y
- 585 43. The Guardian. Covid: UK woman who was first in world to receive vaccine has second
586 dose. *The Guardian*. 29 Dec 2020. Available:
587 [https://www.theguardian.com/world/2020/dec/29/first-person-to-get-covid-jab-receives-
588 follow-up-dose](https://www.theguardian.com/world/2020/dec/29/first-person-to-get-covid-jab-receives-follow-up-dose). Accessed 11 Jan 2023.
- 589 44. Arksey H, O'Malley L. Scoping studies: towards a methodological framework.
590 *International Journal of Social Research Methodology*. 2005;8: 19–32.
591 doi:10.1080/1364557032000119616
- 592 45. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
593 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*.
594 2021;372: n71. doi:10.1136/bmj.n71
- 595 46. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer
596 Review of Electronic Search Strategies: 2015 Guideline Statement. *Journal of Clinical
597 Epidemiology*. 2016;75: 40–46. doi:10.1016/j.jclinepi.2016.01.021

- 598 47. Abdullahi LH, Kagina BM, Ndze VN, Hussey GD, Wiysonge CS. Improving vaccination
599 uptake among adolescents. *Cochrane Database of Systematic Reviews*. 2020 [cited 18 Jan
600 2023]. doi:10.1002/14651858.CD011895.pub2
- 601 48. Cooper S, Schmidt B-M, Sambala EZ, Swartz A, Colvin CJ, Leon N, et al. Factors that
602 influence parents' and informal caregivers' views and practices regarding routine childhood
603 vaccination: a qualitative evidence synthesis. *Cochrane Database of Systematic Reviews*.
604 2021 [cited 18 Jan 2023]. doi:10.1002/14651858.CD013265.pub2
- 605 49. Hope MO, Taggart T, Galbraith-Gyan KV, Nyhan K. Black Caribbean Emerging Adults: A
606 Systematic Review of Religion and Health. *J Relig Health*. 2020;59: 431–451.
607 doi:10.1007/s10943-019-00932-5
- 608 50. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
609 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern
610 Med*. 2018;169: 467–473. doi:10.7326/M18-0850
- 611 51. Etowa J, Demeke J, Abrha G, Worku F, Ajiboye W, Beauchamp S, et al. Social
612 determinants of the disproportionately higher rates of COVID-19 infection among African
613 Caribbean and Black (ACB) population: A systematic review protocol. *J Public Health Res*.
614 2021;11: 2274. doi:10.4081/jphr.2021.2274

615

616

617

618

619

620

621

622

623

624

625

626

627